Psychiatric disorders
21 public biotech companies we cover are developing treatments for depression, schizophrenia, anxiety, PTSD, addiction and related conditions. 11 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Achieve Life Sciences (ACHV)Thesis Challenged
Smoking cessation, Nicotine dependence, E-cigarette (vaping) cessation, E-cigarette or vaping cessation
- Altimmune (ALT)Thesis Intact
Alcohol use disorder
- Anavex Life Sciences (AVXL)Thesis Broken
Schizophrenia
- Aquestive Therapeutics (AQST)Thesis Challenged
Opioid dependence
- Aytu BioPharma (AYTU)Thesis Challenged
Major depressive disorder, Attention deficit hyperactivity disorder
- Biohaven (BHVN)Thesis Challenged
Major depressive disorder
- Cingulate (CING)Thesis Challenged
ADHD, Anxiety, Anxiety disorder, Attention deficit/hyperactivity disorder
- COMPASS Pathways (CMPS)Thesis Intact
Treatment-resistant depression, Post-traumatic stress disorder
- Contineum Therapeutics (CTNM)Thesis Challenged
Major depressive disorder
- Cybin D/B/A Helus Pharma (HELP)Thesis Intact
Major Depressive Disorder, Generalized Anxiety Disorder
- Definium Therapeutics (DFTX)Thesis Intact
Major depressive disorder, Generalized anxiety disorder, Posttraumatic stress disorder
- Lipocine (LPCN)Thesis Broken
Postpartum depression, Major Depressive Disorder
- Neumora Therapeutics (NMRA)Thesis Intact
Schizophrenia
- Neuphoria Therapeutics (NEUP)Thesis Challenged
Social anxiety disorder
- NRx Pharmaceuticals (NRXP)Thesis Challenged
Depression, Schizophrenia, Bipolar Depression, Treatment-Resistant Depression
- Omeros (OMER)Thesis Challenged
Cocaine use disorder
- Ovid Therapeutics (OVID)Thesis Intact
Psychosis, Schizophrenia, Acute schizophrenia
- Praxis Precision Medicines (PRAX)Thesis Intact
Autism spectrum disorder
- TG Therapeutics (TGTX)Thesis Intact
Treatment-resistant schizophrenia
- Tonix Pharmaceuticals (TNXP)Thesis Challenged
Cocaine intoxication, Acute stress disorder, Binge eating disorder, Autism spectrum disorder, and 1 more
- Xenon Pharmaceuticals (XENE)Thesis Challenged
Bipolar depression, Major depressive disorder
Upcoming catalysts
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in Q4 2026
- Q4 2026Cytisinicline · NDA resubmission · Nicotine dependence · smoking cessation
- Q4 2026COMP360 · NDA submission · Treatment-resistant depression
- Q4 2026HLP003 · Phase 3 topline results (APPROACH) · Major Depressive Disorder
Expected in H2 2026
- H2 2026BHV-7000 · Phase 3 topline results · Major depressive disorder
- H2 2026NMRA-861 · Phase 1 results · Schizophrenia
- H2 2026NMRA-898 · Results · Schizophrenia
- H2 2026OV4071 · Trial start · Psychosis · proof-of-mechanism
Expected by end of 2026
- year-end 2026OMS527 · Phase 1b results · Cocaine use disorder
Expected in Q1 2027
- Q1 2027Azetukalner · Phase 3 topline results (X-NOVA2) · Major depressive disorder
Expected in H1 2027
- H1 2027DT120 ODT · NDA submission · Generalized anxiety disorder
Expected by end of June 2027
- Mid-2027TNX-102 SL · Phase 2 topline results (OASIS) · Acute stress disorder · acute stress reaction